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Abstract
Objective—A combination of antibiotics, including but not limited to metronidazole (MET) and 
ciprofloxacin (CIP), has been indicated to eradicate bacteria in necrotic immature permanent teeth 
prior to regenerative procedures. It has been shown clinically that antibiotic pastes may lead to 
substantial stem cell death. The aim of this study was to synthesize scaffolds containing various 
concentrations of CIP to enhance cell viability while preserving antimicrobial properties.
Design—Polydioxanone (PDS)-based electrospun scaffolds were processed with decreasing CIP 
concentrations (25 – 1 wt.%) and morphologically evaluated using scanning electron microscopy 
(SEM). Cytotoxicity assays were performed to determine whether the amount of CIP released 
from the scaffolds would lead to human dental pulp stem cell (hDPSC) toxicity. Similarly, WST-1 
assays were performed to evaluate the impact of CIP release on hDPSC proliferation. Pure PDS 
scaffolds and saturated double antibiotic solution MET/CIP (DAP) served as both positive and 
negative controls, respectively. Antibacterial efficacy against E. faecalis (Ef) was tested.
Results—A significant decrease in hDPSC’ viability at concentrations 5–25 wt.% was observed. 
However, concentrations below 5 wt.% did not impair cell viability. Data from the WST-1 assays 
indicated no detrimental impact on cell proliferation for scaffolds containing 2.5 wt.% CIP or less. 
Significant antimicrobial properties were seen for CIP-scaffolds at lower concentrations (i.e., 1 
and 2.5 wt.%).
Conclusion—The obtained data demonstrated that a reduced concentration of CIP incorporated 
into PDS-based scaffolds maintains its antimicrobial properties while enhancing viability and 
proliferation of dental pulp stem cells.
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1. Introduction
The dental pulp plays a vital role in tooth development as it harbors odontoblasts, highly 
specialized cells that synthesize dentin.1 Traumatic injuries or bacterial infection of the 
dental pulp lead to inflammation and, if not interrupted, to necrosis.2 In children, pulpal 
necrosis promotes the death of odontoblasts, resulting in the disruption of root 
development.3
Traditionally, traumatic tooth injuries with incomplete apical development have undergone 
apexification therapy through placement of intracanal calcium hydroxide, or most recently, 
mineral trioxide aggregate.3,4 Nevertheless, while apexification therapy promotes merely 
apical closure, it does not allow for root development.4 Meanwhile, clinical evidence (e.g., 
root-end development with dentinal walls thickening) has been mounting following 
treatment of necrotic immature teeth with the revascularization technique.5–8
In essence, in the currently advocated regenerative endodontics procedure, a combination of 
antibiotics, including but not limited to metronidazole (MET) and ciprofloxacin (CIP), has 
been indicated to obtain maximum bacteria eradication.3,5,9–11 Microbial elimination must 
be achieved with minimal root canal instrumentation to preserve undifferentiated cells.3,11 
Following root canal decontamination, a tissue engineering-based approach, occurs through 
the process of provoking intentional bleeding in the periapical region, where a fibrin-based 
matrix is formed that ends up serving as a scaffold to support the attachment, proliferation 
and differentiation of stem cells from the apical papillae, thanks to the contribution of 
endogenously-produced growth factors.2,4 Most importantly, according to the literature, the 
demonstration of pulp-like tissue formation after revascularization has been observed only 
on a recent study.12 Meanwhile, the vast majority of studies, including both data from 
animal models and clinical cases, generally reports that the newly formed invaginated tissue 
to be composed of periapical tissue containing bone-like hard tissue and the root canal walls 
thickening is due to the formation of a cementum-like tissue.13,14
Despite encouraging evidence, intrinsic patient-to-patient variability in cell populations and 
the quantity and variety of growth factors,3 combined with the extreme stem cell toxicity 
linked with the use of irrigants and antibiotics,15,16 have suggested the opportunity of using 
antibiotic-containing fibrous scaffolds capable of functioning as a drug delivery system to 
eliminate root canal infection while preserving stem cell viability.17,18 Based on the 
aforementioned considerations, the aim of this study was to synthesize, via electrospinning, 
fibrous-based scaffolds containing distinct CIP concentrations to enhance dental pulp stem 
cell viability while preserving antimicrobial properties.
2. Materials and Methods
2.1. Synthesis of ciprofloxacin-containing fibrous scaffolds
Ciprofloxacin-containing (CIP, Sigma-Aldrich, St. Louis, MO, USA) polydioxanone-based 
(PDSII®, Ethicon Inc, Somerville, NJ, USA) polymer solutions were prepared to synthesize 
scaffolds with selected CIP concentrations, following standard procedures as recently 
reported.17–20 First, violet-colored PDS suture filaments were cut into pieces of similar 
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length (i.e., 3 cm) and de-stained by immersion in dichloromethane (Sigma-Aldrich) for 48 
h. Second, de-stained PDS was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFP, Sigma-
Aldrich) at a concentration of 10 wt.% overnight by using vigorous stirring. Lastly, CIP 
powder was added to the prepared PDS solutions at increasing concentrations (1, 2.5, 5, 10, 
15, 20, and 25 wt.%, in respect to the polymer weight – i.e., 6, 15, 30, 60, 90, 120, and 150 
mg, respectively), and then mixed overnight. The distinct CIP-containing PDS solutions and 
pure PDS (control) were spun into fibers (hereafter referred to as scaffolds) at room 
temperature (RT) onto an aluminum foil covered rotating (120 rpm) stainless steel mandrel 
by loading the solutions into plastic syringes (Becton-Dickinson & Company, Franklin 
Lakes, NJ, USA) fitted with a 27G metallic blunt-tip needle using previously optimized 
parameters (i.e., flow rate 2 mL/h, distance tip-collector 18 cm, and 15–18 kV). The 
scaffolds were vacuum dried at RT for at least 48 h prior to testing. 17–20 Scanning electron 
microscopy (SEM, JSM-5310LV, JEOL, Tokyo, Japan) was used to evaluate fiber 
morphology of the synthesized scaffolds. The fiber diameter was evaluated using Image-J 
software (NIH, Bethesda, MD, USA). 17–20
2.2. Cell culture for viability and proliferation assays
Low glucose Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Grand Island, NY, 
USA) supplemented with 10% FBS (Hyclone Laboratories Inc, Logan, UT), and 1% 
penicillin–streptomycin (Sigma-Aldrich) placed in a humidified incubator at 37°C, with 5% 
CO2, was used to culture human dental pulp stem cells (hDPSC, AllCells LLC, Alameda, 
CA, USA) obtained from permanent third molars. 17,18 The medium was changed every 2–3 
days and cells at passages 4–6 were used.
2.3. Cytotoxicity assays
To evaluate the potentially toxic effects of CIP-containing scaffolds on human dental pulp 
stem cells, cytotoxicity assays according to the guidelines provided by the International 
Standards Organization (ISO, 1993)21 were performed. All scaffolds (15×15 mm2) were first 
sterilized by UV radiation (30 min each side), followed by 30 min immersion in 70% 
ethanol.17,18 After rinsing with sterile PBS (5 min, 2×), extracts from the distinct scaffolds 
were prepared. The assay evaluates the toxic effects of any leachable compound(s) (e.g., 
released ciprofloxacin) when in contact with the cells. Sterile scaffolds (surface ratio = 1 
cm2/mL of medium) were incubated in DMEM at 37°C for 2 days under a 5% CO2 
humidified atmosphere. 17,18 Extracts of sterile ultra-high molecular weight polyethylene 
(UHMWPE) were prepared as a negative control. Supernatants were filtered through a 
Millipore® membrane, and serial dilutions were obtained from the extracts. The dilutions 
were also prepared for a 0.3 vol % phenol solution to serve as the positive control.17,18 
Cytotoxicity tests at each dilution were carried out in quadruplicate. Briefly, hDPSCs at a 
density of 3×103/well were seeded and allowed to adhere in the wells of 96-well tissue 
culture plates. After 4 h, the media was replaced by distinct extract concentrations.17,18 100 
μL of each extract was pipetted into each well. Control columns of four wells were prepared 
with medium without cells (blank), and medium with cells but without the extract (100% 
survival). The plates were incubated under a 5% CO2 humidified atmosphere. Next, 20 μL of 
CellTiter 96 AQueous One Solution Reagent (Promega Corporation, Madison, WI, USA) 
was added after 3 days.17,18 The reagent was allowed to react for 2 h at the same conditions. 
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Incorporated dye was measured by reading the absorbance at 490 nm in a microplate reader 
against a blank column.17,18
2.4. Proliferation assays (WST-1)
hDPSCs were harvested by trypsinization, counted, and seeded on 13-mm treated cell 
culture coverslips (Thermanox, Thermo Fisher Scientific Inc, Rochester, NY, USA) in 24-
well plates at a density of 104/well (1500 μL of culture medium). Meanwhile, scaffolds 
(15×15 mm2, n=4–6/group) were mounted in plastic CellCrownTM (Scaffdex, Tampere, 
Finland), disinfected in 70% ethanol for 30 min, and rinsed twice in sterile PBS (Sigma). 
After a 4 h incubation period to allow cell attachment, the CellCrowns with scaffolds were 
introduced into the wells. A 2 mm distance between the cells and scaffold was achieved 
using plastic rings for standardization purposes. Control (blank) columns were prepared in 
medium without cells and in medium with cells but without scaffold (100% survival). A 
saturated solution (50 mg/mL) of CIP in DMEM was prepared by stirring for 4 h, at RT, 
followed by centrifugation (3000 rpm) for 15 min. Clear supernatant was filter sterilized 
using a 0.22 μm syringe filter.
WST-1 (Roche Diagnostics, Mannheim, Germany) assay was used to evaluate the effects of 
CIP-containing scaffolds on hDPSC proliferation up to 7 days of cell/scaffold exposure.20 
After 3, 5, and 7 days, the CellCrowns with scaffolds were removed. A 500-μL quantity of 
DMEM was left in each well. Next, WST-1 reagent was added at the ratio of 10:1 (i.e., 50 
μL) into each well. After 2 h of incubation in 5%CO2 in a humidified atmosphere at 37°C, 
100 μL of the total volume present in each well was transferred into 96-well plates.20 Full 
medium with cells without scaffold exposure and full medium without cells were assigned 
as positive and negative controls, respectively. Optical density (OD) of the incorporated dye 
was determined by reading the absorbance at 450 nm in a microplate reader against a blank 
column.20 Proliferation was calculated as a ratio of OD from experimental value to positive 
control; both were subtracted by the negative control.20
2.5. Antimicrobial testing
Agar diffusion assays were used to determine the antimicrobial efficacy of CIP-containing 
scaffolds against Enterococcus faecalis (Ef) (ATCC 29212).17,18 According to our recent 
findings, similarly prepared CIP-containing scaffolds at concentrations of 5 and 25 wt.% 
have demonstrated significant antimicrobial activity against Ef.17 Thus, here we proposed to 
investigate whether or not scaffolds containing lower CIP concentrations (e.g., 1 and 2.5 wt
%) would still preserve the antimicrobial properties. Ef was aerobically cultured for 24 h in 
5%CO2 at 37°C in brain heart infusion broth (BHI).17,18 Next, UV sterilized disk-shaped (6 
mm in diameter) samples (n=4) from 3 experimental groups (i.e., 1, 2.5, and 5 wt.%CIP) 
were placed on blood agar plates containing Ef bacterial lawns.17,18 Chlorhexidine (0.12%) 
and 0.9% sterile saline solution were used as positive and negative controls, respectively. 
After 3 days of incubation, the inhibition zones (in mm) were recorded.17,18
2.6. Statistical analysis
One-way analyses of variance (ANOVAs) followed by Tukey’s multiple comparisons were 
used to evaluate differences in fiber diameter. Meanwhile, cell viability (cytotoxicity) and 
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proliferation data were analyzed using two-way ANOVA. The comparisons for inhibition 
zones were performed using mixed-model ANOVA. The significance level was set at 
p<0.05.
3. Results
Representative SEM micrographs of the synthesized micro/nano fibrous scaffolds are shown 
in Figure 1. Mean fiber diameter ranged from 1139±348 nm (PDS, control) to 748±231 nm 
(25 wt.% CIP). Generally, CIP concentrations above 5 wt.% led to the formation of fibers 
with significantly (p<.001) smaller diameters than PDS.
Based on the intended clinical use of the current antibiotic-containing scaffolds as a 
disinfection strategy prior to regenerative endodontics procedures, the cytotoxic effects of all 
scaffolds were assessed to determine whether the amount of CIP released would indeed lead 
to cell toxicity. Cytotoxicity assays revealed a significant decrease in cell viability at 
concentrations 5–25 wt.% (Fig. 2). Then, we processed CIP-containing scaffolds at lower 
concentrations (i.e., 1 and 2.5 wt.%) to determine the optimal, non-toxic CIP concentration 
that can be incorporated without impairing cell viability. The assay was run again using 
similar controls but with CIP-containing scaffolds with concentrations from 1–5 wt.%. Fig. 
2B shows the cell viability data, where concentrations lower than 5 wt.% can be seen not to 
impair hDPSCs viability. Similarly, we evaluated the indirect effects of CIP release from the 
scaffolds on the proliferation ability of hDPSC by incubating the cells in the presence of 
scaffolds up to 7 days. Data revealed that scaffolds containing 5 to 25 wt. % of CIP inhibited 
cell proliferation at all-time points (Fig. 3). No inhibitory effects on hDPSC proliferation 
were seen after exposure to 1 and 2.5 wt.%CIP-containing scaffolds (Fig 4). The 
cytocompatibility data presented in this study agree with our previous work. However, since 
decreasing CIP concentrations to 1 and 2.5 wt% revealed no significant impact on cell 
viability/proliferation, we proposed to examine whether these scaffolds would indeed 
present antimicrobial properties. Agar diffusion data demonstrated significant growth 
inhibition of E. faecalis associated with the use of CIP-containing scaffolds at concentrations 
lower than 5 wt.% (Fig. 5).
4. Discussion
Eradication of infection from necrotic teeth is a vital step prior to regenerative endodontics 
procedures.3,5,9–11 It is now well-established that antibiotic mixtures, such as the so-called 
double (MET and CIP) and triple (MET, CIP, and minocycline) antibiotic pastes are 
excellent in providing a bacteria-free niche9–11; however, they decrease viability of dental 
pulp stem cells involved in tissue regeneration.15,16 Lately, our group has proposed a drug 
delivery strategy based on the use of antibiotic-containing electrospun scaffolds, with 
significant clinical potential in endodontics for the disinfection step involved in the current 
clinically advocated regenerative strategy.17,18 Taken together, our recent data has proven 
that a variety of antibiotic drugs (i.e., MET, CIP and MET/CIP bi-mix formulations) can be 
successfully spun into fibrous scaffolds, with significant antimicrobial efficacy against 
sensitive bacteria.17–19 Nevertheless, despite markedly lower antibiotic concentrations being 
released from these scaffolds when compared with actual antibiotic concentrations used 
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clinically, we have also reported a considerably negative impact on hDPSCs survival after 
exposure to CIP-containing scaffolds, not to MET-containing scaffolds.17
Quinolones, including CIP, are broad spectrum antibiotics, commonly used against a wide 
range of both gram-positive and gram-negative bacteria.22 The mechanism of action23 
involves the inhibition of bacterial DNA topoisomerase II (gyrase) and topoisomerase IV, 
which are enzymes involved in untwining bacterial DNA during the replication process. 
Regrettably, CIP has also been shown to decrease the viability of eukaryotic cells, leading to 
multiple adverse effects24,25, such as tendinopathies26 and peripheral neuropathy27,28, due to 
a decline in the synthesis of proteins encoded in mitochondrial deoxyribonucleic acid 
(mtDNA). Analysis of mtDNA from CIP-treated cells revealed the presence of site-specific, 
double-stranded DNA breaks29, which were attributed to inhibition of mitochondrial 
topoisomerase II activity, functionally and structurally similar to that found in bacteria.30 
Taken together, mammalian cells are therefore susceptible to CIP toxic effects, particularly 
cells with high proliferation rates, i.e., human hematopoietic stem cells31,32, embryonic stem 
cells (hESCs)33, and dental-related cells.15,16 Worth mentioning, one should note that the 
cytotoxic effects associated with CIP also depend on the dosage and time of exposure. In a 
recent in vitro study, embryonic stem cells were able to regain baseline metabolic activity 
after CIP withdrawal33; thus, decreasing the drug concentration or/and time of exposure may 
significantly improve stem cells viability. Based on the aforementioned, here we investigated 
whether synthesis, via electrospinning, of the CIP-containing scaffolds with reduced CIP 
concentrations would enhance dental pulp stem cell viability, while preserving antimicrobial 
properties. In our previous study17, we demonstrated that CIP at 5 wt.% had comparable 
antimicrobial efficacy to 25 wt.%. The data obtained herein revealed that scaffolds 
containing lower CIP concentrations (e.g., 1 and 2.5 wt.%) not only sustained the 
antimicrobial properties but more importantly they significantly reduced the negative impact 
on hDPSC viability/proliferation.
5. Conclusions
In conclusion, data from this study demonstrated that reducing the amount of CIP 
incorporated into PDS-based scaffolds enhances hDPSCs viability and proliferation while 
preserving its antimicrobial properties.
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Fig. 1. 
Representative SEM micrographs of the scaffolds (5000×): (A) pure PDS, (B) 1 wt.% CIP, 
(C) 2.5 wt.%CIP, (D) 5 wt.%CIP, (E) 10 wt.%CIP, (F) 15 wt.%CIP, (G) 20 wt.%CIP, and (H) 
25 wt.%CIP.
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Fig. 2. 
Cytotoxic effects of extracts prepared from scaffolds with selected CIP concentrations. 
hDPSCs were exposed to increasing extracts concentration, namely 6.25%, 12.5%, 25%, 
50%, and 100%. Cell viability (%) was determined after 72 hours. *Significant differences 
from the control were set at p < 0.05.
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Fig. 3. 
Proliferation (%) of hDPSCs after exposure to CIP-containing scaffolds (5 – 25 wt.%). 
Proliferation was determined at days 3, 5 and 7. Data were analyzed using one-way ANOVA 
and Tukey’s multiple comparison tests. *Significant differences between experimental 
groups and the control, at the same time point, were set at p < 0.05.
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Fig. 4. 
Proliferation (%) of hDPSCs after exposure to CIP-containing scaffolds (1 – 5 wt.%). 
Proliferation was determined at days 3, 5 and 7. Significant differences from the control 
(PDS) and other groups were set at p < 0.05 and represented using lower case letters.
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Fig. 5. 
Effects of CIP-containing scaffolds on the growth inhibition of Ef. (A-B) Representative 
macrophotographs of agar diffusion assays on Ef, with 1 wt.%, 2.5 wt.%, and 5 wt.% CIP-
containing scaffolds. Sterile saline (Sal) and 0.12% chlorhexidine (CHX) solutions were 
used as negative and positive controls, respectively. (C) Data from the agar diffusion assays 
at day 3 (n=4). Significant difference between groups is denoted with an asterisk (p < 0.05).
Kamocki et al. Page 13
Arch Oral Biol. Author manuscript; available in PMC 2017 March 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
